DOCSLIB.ORG

Pharmaceutical Manufacturing Plan for Africa Business Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Manufacturing Plan for Africa Business Plan Printed in Austria V1-November 2012 PHARMACEUTICAL M ANUFACTURING PLAN FOR A FRICA - Business Plan PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA Business Plan African Union Commission P.O. Box 3243, Roosvelt Street (Old Airport Area), W21K19 Addis Ababa, Ethiopia Internet: www.au.int This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as “developed”, “industrialized” and “developing” are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. The opinions, statistical data and estimates contained in signed articles are the responsibility of the author(s) and should not necessarily be considered as reflecting the views or bearing the endorsement of UNIDO. Although great care has been taken to maintain the accuracy of information herein, neither UNIDO nor its Member States assume any responsibility for consequences which may arise from the use of the material. Cover photographs Left image Shutterstock, Inc. Middle image Shutterstock, Inc. Right image Shutterstock, Inc. PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA Business Plan Addis Ababa, 2012 ACKNOWLEDGEMENT This Business Plan was developed by a partnership of the African Union Commission (AUC) and the United Nations Industrial Development Organization (UNIDO) to accel- erate the implementation of the Pharmaceutical Manufacturing Plan for Africa (PMPA), with funding from the German government. The Commission therefore extends special appreciation to UNIDO for the resourceful collaboration through which this Business Plan has been developed. The Commission greatly appreciates all member states constituting the Technical Com- mittee of the Pharmaceutical Manufacturing Plan for Africa from North Africa (Egypt and Libya), West Africa (Ghana, Nigeria and Senegal), Central Africa (Burundi, Cameroon and Gabon), East Africa (Kenya and Ethiopia) and Southern Africa (South Africa and Angola) for their support to the process. The Commission further wishes to recognize the effort of other members of the Technical Committee such as NEPAD Planning and Coordinating Agency, WHO, UNAIDS, Region- al Economic Communities, Southern African Generic Manufacturers Association, Fed- eration of African Pharmaceutical Manufacturers Associations, COHRED, EDCTP, and ANDI, who since joining the Technical Committee, have supported the implementation of its broadened mandate. The Commission thanks all the organizations including members of the consortium of the AMRH Programme that are supporting Africa’s development agenda through implement- ing programmes geared towards promoting access to quality affordable medicines. The Commission acknowledges the efforts of the authors of the Business Plan, a team com- posed of Dr. Skhumbuzo Ngozwana & Mr. Alastair West from UNIDO and Dr. Ademola Olajide & Dr. Janet Byaruhanga from the Health, Nutrition and Population Division of the AUC Department of Social Affairs. FOREWORD During the last decade promoting sustainable access to quality and affordable medicines and integrating local production as part of the overall health systems strengthening package has been of significant concern to African leaders. A viable pharmaceutical industry in Africa shall not only impact on the African health sys- tem and its capacity to respond to the health needs of the people but also will contribute to the overall socioeconomic development of the continent. For this reason, African governments have committed to enhancing the attainment of one of the set targets of the 8th Millennium Development Goal, to increase the proportion of the population with access to affordable essential drugs on a sustainable basis. The African Union Commission has been at the forefront in galvanizing the necessary po- litical will and providing the leadership to the broad range of processes required for promot- ing a sustainable local pharmaceutical industry. The Commission has made significant efforts towards ensuring delivery on set objectives of Africa’s highest decision making body (The Assembly of Heads of State and Government) as they relate to the implementation of a Pharmaceutical Manufacturing Plan for Africa (PMPA). These range from conducting studies to establish Africa’s local pharma production capacity, building strategic partnerships required for the development of a concrete action plan, to engaging governments in the development of the Business Plan for the operation- alization of the PMPA. This Business Plan is a product of multi-stakeholder efforts all geared towards providing a package of solutions to address the various challenges confronting the African pharma sec- tor in general. It is not an end in itself but rather a means through which governments either through their national systems or regional economic communities will engage with relevant partners to implement specific activities according to their unique needs/priorities. The road ahead remains long and challenging but the desired objectives remain compelling and non-negotiable. Consequently I invite all stakeholders from member state governments to Regional Economic Communities; from the Private for Profit Sector to Donors and De- velopment partners to strategically engage and collaborate, creating the unity of purpose and necessary synergies to realize the noble objectives of this Business Plan. Bience P. Gawanas Commissioner for Social Affairs iii iv CONTENTS ACKNOWLEDGEMENT ........................................................................................................... ii FOREWORD .......................................................................................................................... iii List of Abbreviations .......................................................................................................... vii List of Figures ....................................................................................................................... x List of Tables ....................................................................................................................... xi EXECUTIVE SUMMARY ..........................................................................................................1 SWOT ANALYSIS ...................................................................................................................6 1. Introduction and Background ..........................................................................................11 1.1 THE STRATEGIC CONTEXT OF AFRICA’S HEALTHCARE CHALLENGES ................................ 12 1.2 THE PHARMACEUTICAL MANUFACTURING PLAN FOR AFRICA ........................................... 18 1.3 BUSINESS PLAN ................................................................................................................20 1.4 SUMMARY OF CHAPTER 1 .................................................................................................22 2. Overview of Pharmaceutical Manufacturing in Africa .................................................... 25 2.1 INTRODUCTION: THE PHARMACEUTICAL MANUFACTURING SYSTEM ................................25 2.2 THE CURRENT STATUS OF THE PHARMACEUTICAL INDUSTRY AND OTHER STAKEHOLDERS ...................................................................................................29 2.3 CHALLENGES AND OPPORTUNITIES FOR LOCAL PRODUCTION ........................................47 2.4 SUMMARY OF CHAPTER 2 ................................................................................................54 3. Solutions .........................................................................................................................57 3.1 THE GENERIC SOLUTIONS PACKAGE .................................................................................58 3.2 OTHER ACTIVITIES ...........................................................................................................77 3.3 SUMMARY OF CHAPTER 3 ................................................................................................82 4. Implementation Plan ..................................................................................................... 85 4.1 PHASED APPROACH TO IMPLEMENTATION ......................................................................86 4.2 STAKEHOLDER ENGAGEMENT .......................................................................................... 91 4.3 PROPOSED STRUCTURE FOR DELIVERING THE PMPA ....................................................93 4.4 RESOURCE REQUIREMENTS ............................................................................................95 4.5 MONITORING AND EVALUATION .......................................................................................99 4.6 RISK MANAGEMENT.........................................................................................................101 4.7 SUMMARY OF CHAPTER 4 .............................................................................................. 102
Load more

Recommended publications
  • Algiers Economic Opportunity Analysis
    Algeria Entrepreneurship & Employment Project Algiers Economic Opportunity Analysis Version: April 13, 2020 By Eleanor Sohnen Methodology designed by Dr. Catherine Honeyman Research conducted by Mehdi Bentoumi Contents Contents . 2 Algeria Entrepreneurship Executive Summary . 3 & Employment Industry sector priorities and rationale . 4 Project Launched: Mapping Supply Chains and Identifying Needs and Opportunities . 5 October 2019 Funder: U.S. Agribusiness/Food Processing . 5 Department of State Middle East Partnership Initiative Supply Chain Map of the Sector . 7 (MEPI) Analysis of needs to support SME business growth in the sector . 8 Analysis of opportunities in the sector . 8 Local partners: Pharmaceuticals . 8 ◆ Algerian Center for Social Supply Chain Map of the Sector . 10 Entrepreneurship (ACSE) Analysis of needs to support SME business growth in the sector . 11 ◆ MBI (Setif) Analysis of opportunities in the sector . 11 Information and Communications Technology (ICT) . 11 Process Map Example: Mobile Application Development . .12 Analysis of needs to support SME business growth in the sector . .12 Analysis of opportunities in the sector . 12 Conclusions . 13 Analysis of needs to support SME business growth across the three sectors . 13 Analysis of opportunities across the three sectors . 13 Demand-driven training and recruitment . 13 New business creation to supply B2B products and services across the three sectors . .15 Policy Issues . 17 Next Steps . 17 SME priority partners . 17 Annex A: Economic Opportunity Analysis Methodology . 18 Annex B: Sector Analysis–Algiers . 28 2 World Learning Algeria Algiers Economic Opportunity Analysis - Version April 13, 2020 Executive Summary The wilaya of Algiers, with a population of 3.2 million as of the end of 2017, is the country’s admin- istrative, political, and economic capital.
    [Show full text]
  • Download File (Pdf)
    2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION 2021 FORUM REPORT COVID-19 in Africa one year on: Impact and Prospects MO IBRAHIM FOUNDATION Foreword by Mo Ibrahim Notwithstanding these measures, on current projections Founder and Chair of the Mo Ibrahim Africa might not be adequately covered before 2023. Foundation (MIF) Vaccinating Africa is an urgent matter of global security and all the generous commitments made by Africa’s partners must now be delivered. Looking ahead - and inevitably there will be future pandemics - Africa needs to significantly enhance its Over a year ago, the emergence and the spread of COVID-19 homegrown vaccine manufacturing capacity. shook the world and changed life as we knew it. Planes were Africa’s progress towards its development agendas was off grounded, borders were closed, cities were shut down and course even before COVID-19 hit and recent events have people were told to stay at home. Other regions were hit created new setbacks for human development. With very earlier and harder, but Africa has not been spared from the limited access to remote learning, Africa’s youth missed out pandemic and its impact. on seven months of schooling. Women and girls especially The 2021 Ibrahim Forum Report provides a comprehensive are facing increased vulnerabilities, including rising gender- analysis of this impact from the perspectives of health, based violence. society, politics, and economics. Informed by the latest data, The strong economic and social impacts of the pandemic it sets out the challenges exposed by the pandemic and the are likely to create new triggers for instability and insecurity.
    [Show full text]
  • WHA53-2000-REC-2-Eng-Fre.Pdf
    WНASЗ /2000/REC/2 WORLD HEALTH ORGANIZA TION ORGANISAТION MONDIALE DE LA SANTE FIFTY-THIRD WORLD HEALTH ASSEMBLY GENEVA, 15-20 МАУ 2000 VERBATIМ RECORDS OF PLENARY MEETINGS AND LIST OF PARTICIPANTS ' CINQUANTE-TROISIEME, ASSEMBLEE MONDIALE, DELASANTE GENEVE, 15-20 МАI 2000 COMPTES RENDUS IN EXTENSO DES SEANCES PLENIERES ЕТ LISTE DES PARTICIPANTS GENEVA GENEVE 2000 WНASЗ/2000/REC/2 WORLD HEALTH ORGANIZAТION ORGANISAТION MONDIALE DE LA SANTE FIFTY-THIRD WORLD HEALTH ASSEMBLY GENEVA, 15-20 МАУ 2000 VERBATIM RECORDS OF PLENARY MEETINGS AND LIST OF PARTICIPANTS CINQUANTE-TROISIEME' ASSEMBLЙE MONDIALE, DELASANTE GENEVE, 15-20 МАI 2000 COMPTES RENDUS IN EXTENSO DES SEANCES PLENIERES ЕТ LISTE DES PARTICIPANTS GENEYA GENEVE 2000 PREFACE The Fifty-third World Health AssemЫy was held at the Palais des Nations, Geneva, from 15 to 20 Мау 2000, in accordance with the decision of the Executive Board at its 104th session. Its proceedings are issued in three volumes, containing, in addition to other relevant material: Resolutions and decisions, annex- document WНA53/2000/REC/l Verbatim records of plenary meetings, list of participants- document WНA53/2000/REC/2 Summary records of committees and ministerial round taЫes, reports of committees - document WНA53/2000/REC/3 For а list of abbreviations used in these volumes, the officers of the Health AssemЬly and membership of its committees, the agenda and the list of documents for the session, see preliminary pages of document WНA53/2000/REC/l. In these verbatim records, speeches delivered in Arabic, Chinese, English, French, Russian or Spanish are reproduced in the language used Ьу the speaker; speeches delivered in other languages are given in the English or French interpretation.
    [Show full text]
  • June 2020 Africa: the Final Frontier For
    AFRICA: THE FINAL FRONTIER FOR PHARMACEUTICALS COMPLIMENTARY UPDATES AND INTELLIGENCE BRIEFINGS JUNE 2020 1 TABLE OF CONTENTS Africa INSIGHTS P. 03 UNDERSTANDING AFRICA’S PLACE IN THE GLOBAL PHARMA INDUSTRY Improvements & Innovations in African pharma ........................................................................ 4 Africa’s urban middle trigger post-millennium pharma growth ................................................. 4 Regional hubs increase access, but drive growth in counterfeit goods ................................... 4 Asian, European companies and local start-ups are the key players ....................................... 5 Opportunities to consider .............................................................................................................. 6 Establishing regional manufacturing hubs in key locations ........................................................ 6 Closing gaps in existing supply chains ........................................................................................... 7 Consolidating the industry .............................................................................................................. 7 Concluding remarks and key considerations ............................................................................. 8 Playing the long game .................................................................................................................... 8 Africa’s top 10 stories P. 09 Digital healthcare and health insurance on the rise in East Africa ..........................................
    [Show full text]
  • North Africa Biodiversity Programme Phase III: Internal Review
    NORTH AFRICA BIODIVERSITY PROGRAMME, PHASE III INTERNAL REVIEW Meg Gawler Final Report June 2003 Cover photo: Salvia officinalis (sage), used for colds, sore throat, asthma, etc. © Meg Gawler / ARTEMIS Services Report prepared by: Tel: +33 4 5040 7870 Fax: +33 4 5040 7379 Email: [email protected] Web site: http://www.artemis-services.com Founding Director: Meg Gawler North Africa Biodiversity Programme, Phase III – Internal Review Final Report – June 2003 EXECUTIVE SUMMARY With the support of SDC, IUCN has been engaged since 1996 in a programme aimed at promoting: A) the conservation of biodiversity in North Africa, B) a network of institutions from the region in support of this objective, and C) the role of women in biodiversity conservation. The programme is carried out by IUCN State and NGO Members in Algeria, Egypt, Libya, Morocco, and Tunisia. Phase III of the IUCN North Africa Biodiversity Programme covers the period of 1 November 2001 to 31 October 2004, with a budget over the three years of CHF 1’910’000. Of this, the project budget for each of the five implementing countries is on the order of CHF 60’000 per annum. In many countries, the projects also benefit from co-funding secured locally (in cash or in kind). The overall objectives of Phase III are to: 1. Promote the conservation of endangered and economically useful plants in North Africa, with special reference to medicinal and economically useful plants. 2. Promote indigenous knowledge and the equitable participation of people in the management and conservation of endangered and economically useful plants in North Africa.
    [Show full text]
  • Binding Corporate Rules (Bcrs
    SANOFI Group in-house rules on the transfer of personal data (Binding Corporate Rules (BCRs)) INTRODUCTION The Sanofi Group (the “Group”) expresses its commitment to the right to privacy and protection of Personal Data in its Code of Ethics (hereinafter the Code attached as appendix 2) and specifies in its Privacy and Personal Data Protection Policy (hereinafter the Policy attached as appendix 3) the principles to be complied with within the Group in application of the said Code. The Binding Corporate Rules with its Appendices (hereinafter BCRs) of the Sanofi Group finalize the Group’s provisions on the Personal Data Protection. These BCRs are intended to ensure a suitable level of protection in compliance with European Directive 95/46 dated 24 October 1995 when the Personal Data specified in the present document are transferred within the Group for the purposes of the Group’s business. The Policy and the BCRs are in principle complementary documents. In case of contradiction between these documents, the BCR will take precedence when applicable. Words or expressions undefined in the present document and beginning with a capital letter have the meaning given in the Policy. In case of doubt, the content of the BCRs should be interpreted according to the provisions of European Directive 95/46 dated 24 October 1995. I- SCOPE The purpose of the BCRs is to ensure an adequate level of Personal Data protection in the Group Subsidiaries in countries which are not members of the European Economic Area (EEA) in order to allow the Transfer of categories of Personal Data described in Appendix 4 from the Group’s Subsidiaries located in one Member State of the European Economic Area (EEA) to the Group’s Subsidiaries in a Non-Member Country.
    [Show full text]
  • (PCT): Impact Assessment
    Jordan’s Accession to the Patent Cooperation Treaty (PCT): Impact Assessment September 2016 INTRODUCTION ON PATENTS AND THE PATENT COOPERATION TREATY (PCT) WHAT IS A PATENT? “A patent is a document issued by a government office (or a regional office acting for several countries) that describes an invention and creates a legal situation in which the patented invention can be exploited (manufactured, used, sold, imported and licensed) with the authorization of the owner of the patent for a limited time (generally 20 years)” (WIPO) WHAT IS A PATENT? Once an invention is patented, It may not be exploited in the country by persons other than the owner of the patent unless the owner agrees to such exploitation under a licensing agreement. Thus the owner of the invention has the statutory right to prevent others from commercially exploiting his invention CONDITIONS FOR A PATENT? 1. The invention must consist of patentable subject matter. 2. The invention must be industrially applicable (useful) 3. it must be new (novel) 4. it must exhibit sufficient “inventive step” (be non-obvious) 5. The disclosure of the invention in the patent application must meet certain technical standards. WHAT IS THE PCT? 1. The PCT is an international agreement administered by WIPO. 2. The PCT facilitates the acquisition of patent rights in a large number of countries (currently151 contracting states). 3. The PCT streamlines the process of securing patents for an invention in multiple countries by eliminating duplications in filing separate patent applications for the same invention in several countries. WHAT IS THE PCT? The PCT is a patent filing system not a patent granting system The decision to grant patent rights is under the jurisdiction of national patent offices.
    [Show full text]
  • Investing in Algeria Definitif
    Ministry Delegate for Participation and Investment Promotion MDPPI TABLE OF CONTENTS 1. INVESTMENT ENVIRONMENT ......................................................... 16 CHAPTER 1 - PRESENTATION OF ALGERIA ............................................ 16 Geography and Climate .................................................................. 16 Location..................................................................................... 16 Relief ........................................................................................ 17 Climate ...................................................................................... 17 Faun and Flora .............................................................................. 17 Faun.......................................................................................... 18 Flora ......................................................................................... 18 Main Cities of the Country Institutions ................................................ 18 Legislative power.......................................................................... 18 The Constitutional Council................................................................ 19 Executive power........................................................................... 19 Law and Judiciary Power ............................................................... 20 Law .......................................................................................... 20 Judiciary power...........................................................................
    [Show full text]
  • Ministry of Industry and Mines
    Ministry of industry and Mines Ali Oumellal General Director of the merchant Public sector management SUMMARY A. The new investment law B. Rebuilding Sub-sectors C. Public Merchant Sector Modernisation D. Structuring projects carried out or in progress E. What are we looking for? F. In what forms? G. Ongoing partnerships examples A program for economic diversification and the integration of strategic industrial sectors This program is based on: The diversification and performance of domestic production for import substitution. The upgrading of the industrial fabric by targeting upstream development where most of the added value is concentrated by greater local integration. Pass by 2019 from importer to producer stage satisfying a large part of domestic demand and then as exporter of processed goods. The program is structured around a set of priority actions that address both the cross-sectoral and sectoral dimension of industrial development Sectoral The PMS dimension Modernizati on & support to private companies Sub – Sectors Policies & Improvement of the Partnershi investment p environment (availability of land, granting of benefits, quality of accompanying infrastructure, etc. …) Transverse dimension A. The new Investment Law (11) What are the principles and foundations of the new system? Les conditions d’accès aux avantages Conditions to access benefits Investments in economic production of goods activities and services (National and / or foreign investments in partnership) Investments in the creation, extension of production and / or rehabilitation capacities and / or equity investments in a company. Goods constituting external contributions in-kind in the context of relocations & New goods acquired 1- Exemption from customs duties, VAT, land registration tax, registration fees, real estate tax and during the realization, 2- Exemption of 03, 05 or 10 years of the IBS, TAP during the exploitation phase, B.
    [Show full text]
  • Cuban Experience with Local Production of Medicines
    Cuban experience with local production of medicines, technology transfer and improving access to health Cuban experience with local production of medicines, technology transfer and improving access to health Property and Trade Intellectual Innovation R&D, Transfer Technology PAHO LOGO Name Emblem The PAHO logo consists of the PAHO emblem (approImproving Access ved by the Directive Council on September 1978 DC34.R18) together with the name of the Organization. The PAHO logo is a valuable component of the Organization’s intellectual property as it conveys instant association with and recognition of Financing the Organization. The PAHO logo represents the single brand of the Organization and cannot be altered. ISBN 978 92 4 150971 8 Logo (horizontal) Reporting Monitoring and Positive versions The logo of WHO Regional Office for the Americas must be included next to or below the PAHO The horizontal logo is a substitute of the standard logo in cases when the applicability of logo on information products published by PAHO. Both logos should be in the same language as the standard logo is constrained due to space or aesthetic reasons. The cases identified so far for the use of the horizontal logo are: Press Room backdrops, signposting of buildings, the information product on which they appear. e-mail newsletters, Facebook timeline as part of the top image. CMYK Horizontal layout: The WHO logo is displayed next to the PAHO logo. The CMYK horizontal logo is designed for small communication media such as mobile web, electronic newsletters, Facebook pages, PowerPoint presentations, etc. Pantone EC Corporate Blue Vertical layout: The WHO logo is displayed below the PAHO logo.
    [Show full text]
  • Building a Competitive and Socially Inclusive Local
    BUILDING A COMPETITIVE AND SOCIALLY INCLUSIVE LOCAL PHARMACEUTICAL MANUFACTURING IN WEST AFRICA THROUGH ENHANCING RESEARCH, INNOVATION AND INTELLECTUAL PROPERTY Ogada, Tom; ; © 2020, AFRICAN CENTER FOR TECHNOLOGY STUDIES This work is licensed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/legalcode), which permits unrestricted use, distribution, and reproduction, provided the original work is properly credited. Cette œuvre est mise à disposition selon les termes de la licence Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/legalcode), qui permet l’utilisation, la distribution et la reproduction sans restriction, pourvu que le mérite de la création originale soit adéquatement reconnu. IDRC Grant/ Subvention du CRDI: 108349-003-Strengthening partnerships among Africa’s science granting councils and with the private sector FINAL REPORT Building a competitive and socially inclusive local pharmaceutical manufacturing in West Africa through enhancing research, innovation and intellectual property Compiled by Prof Tom Ogada, Team Leader, December 7th, 2019 i Acronyms ACTS African Centre for Technology Studies ARV Antiretroviral ARIPO African Regional Intellectual Property Organization API Active Pharmaceutical Ingredient A/U-I Academia/ University – Industry AMA African Medicine Agency ANRP Advanced Networking Research Price AUC African Union Commission ASET Applied Science, Engineering and Technology ATMs Africa Traditional Medicines BE Bioequivalent BPP Bureau of Public
    [Show full text]
  • Mapping Research Systems in Developing Countries
    Mapping research systems in developing countries Country review template Project Leaders: CREST: Centre for Research on Science and Technology, University of Stellenbosch, South Africa IRD: Institute for Research on Development, France 1 Table of Contents Introduction ....................................................................................................................................... 1 1. The basic template ..................................................................................................................... 2 2. The annotated template ............................................................................................................ 9 Section 1: Contextualization of the science system within broader political, economic, educational and social systems ........................................................................... 9 Section 2: Some considerations about the History of science in the (country, region) under review .................................................................................................... 13 Section 3: The governance of science in the country and available policies (especially S&T, R&D and HE)............................................................................................. 17 Section 4: Informal S&T structures .................................................................................... 21 Section 5: Knowledge and R&D performers ...................................................................... 24 Section 6: S&T Human Resources (Description/statistics
    [Show full text]